tiprankstipranks
Trending News
More News >
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
US Market
Advertisement

PMV Pharmaceuticals (PMVP) AI Stock Analysis

Compare
113 Followers

Top Page

PMVP

PMV Pharmaceuticals

(NASDAQ:PMVP)

Rating:40Underperform
Price Target:
PMV Pharmaceuticals faces significant challenges typical of a biotech firm in the pre-commercialization phase, with no revenue and high R&D costs leading to negative financials. The strong cash position offers some financial flexibility, but the lack of revenue and ongoing losses are significant concerns. Technical indicators suggest a bearish trend, and valuation metrics reflect the company's developmental stage. A path to commercialization is essential for improving financial health and investor confidence.
Positive Factors
Clinical Trials
Enrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy in TP53 Y220C and KRAS WT advanced solid tumors remains on track.
Financial Performance
PMV ended 2024 with $183.3M in cash, which in analyst's view should fund operations to end-2026.
Negative Factors
Clinical Risks
Risks include negative PC14586 clinical data, delays in moving candidates into advanced trials, and setbacks in later-stage studies.
Treatment Deployment
There is a low probability of PC14586 monotherapy deployment in a tumor-agnostic fashion due to the minimum requirement criteria.

PMV Pharmaceuticals (PMVP) vs. SPDR S&P 500 ETF (SPY)

PMV Pharmaceuticals Business Overview & Revenue Model

Company DescriptionPMV Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which are the most common mutations found in human cancers. The company operates within the healthcare and biotechnology sectors, aiming to provide transformative treatments that specifically target cancer's genetic drivers.
How the Company Makes MoneyPMV Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company focuses on advancing its pipeline of small-molecule therapies through clinical trials and aims to monetize these assets via out-licensing agreements, partnerships with larger pharmaceutical companies, or direct sales upon regulatory approval. Key revenue streams include milestone payments, royalties, and upfront fees from partnerships and collaborations, which are essential to funding ongoing research and development efforts. The company's financial success is closely tied to the successful advancement of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

PMV Pharmaceuticals Financial Statement Overview

Summary
PMV Pharmaceuticals is typical of a biotech company in its pre-revenue phase, with significant R&D investments leading to high operational losses and negative cash flows. The strong cash position provides some financial flexibility, but the ongoing lack of revenue generation is a critical issue. The company needs to achieve milestones that could lead to commercialization to improve its financial health and investor confidence.
Income Statement
20
Very Negative
PMV Pharmaceuticals has consistently reported zero revenue over the years, highlighting the typical operational phase of a biotech firm focused on R&D before product commercialization. The net income is negative, with increasing losses, indicating high operational expenses relative to non-existent revenues. The absence of revenue growth and weak profit margins reflect challenges in moving towards profitability.
Balance Sheet
55
Neutral
The company's balance sheet shows a strong equity position with significant cash reserves, providing a buffer against the continued losses. The debt-to-equity ratio is low due to minimal debt levels, which is a positive sign. However, the continuous decline in stockholders' equity and asset base over the years is a concern, indicating potential long-term sustainability issues if the trend continues without revenue generation.
Cash Flow
40
Negative
PMV Pharmaceuticals exhibits negative operating and free cash flows, consistent with its stage in the biotech lifecycle. While free cash flow has improved slightly, it remains negative, reflecting high operational cash usage. The lack of positive cash flow from operations indicates reliance on external financing to sustain operations, posing a risk if capital markets become less favorable.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-1.26M-650.00K-1.28M-318.00K
EBITDA-73.67M-78.88M-76.72M-57.99M-34.62M
Net Income-58.71M-68.96M-73.32M-57.85M-34.44M
Balance Sheet
Total Assets191.29M252.15M270.31M331.57M365.53M
Cash, Cash Equivalents and Short-Term Investments169.45M203.06M241.05M297.16M361.42M
Total Debt1.19M13.29M13.98M11.19M0.00
Total Liabilities15.21M26.46M24.28M23.01M6.41M
Stockholders Equity176.08M225.69M246.03M308.56M359.12M
Cash Flow
Free Cash Flow-51.94M-56.62M-71.74M-47.92M-32.89M
Operating Cash Flow-51.28M-55.66M-63.76M-46.57M-32.74M
Investing Cash Flow53.35M-50.55M-1.37M-143.58M27.91M
Financing Cash Flow313.00K35.58M958.00K2.02M292.97M

PMV Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.35
Price Trends
50DMA
1.09
Positive
100DMA
1.09
Positive
200DMA
1.30
Positive
Market Momentum
MACD
0.08
Negative
RSI
70.38
Negative
STOCH
54.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Positive. The current price of 1.35 is above the 20-day moving average (MA) of 1.25, above the 50-day MA of 1.09, and above the 200-day MA of 1.30, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 70.38 is Negative, neither overbought nor oversold. The STOCH value of 54.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMVP.

PMV Pharmaceuticals Risk Analysis

PMV Pharmaceuticals disclosed 77 risk factors in its most recent earnings report. PMV Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

PMV Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$382.83M4.90-58.97%23.81%146.45%
52
Neutral
$7.62B0.05-63.03%2.44%16.33%0.31%
51
Neutral
$67.06M-221.66%13.83%37.66%
50
Neutral
$57.14M-119.22%25.51%
47
Neutral
$94.04M-196.81%
40
Underperform
$74.81M-32.66%21.33%
39
Underperform
$73.01M-679.15%-56.88%-57.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PMVP
PMV Pharmaceuticals
1.44
-0.21
-12.73%
PDSB
PDS Biotechnology
1.21
-2.73
-69.29%
CTMX
CytomX Therapeutics
2.39
0.97
68.31%
CUE
Cue Biopharma
0.90
0.20
28.57%
STRO
Sutro Biopharma
0.92
-3.36
-78.50%
GUTS
Fractyl Health, Inc.
1.91
-2.13
-52.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 26, 2025